Global Biologics Market—Companies-to-Action
Biopharma Companies are Increasingly Collaborating with CDMOs, CROs, and Digital and Medical Equipment Companies for Biologics Discovery and Development
  • This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products. Across therapy areas, oncology and diabetes emerge as the key contributing segments alongside immunology and cardiovascular diseases. Several small- to mid-sized companies are increasingly focusing on oncology and immunology segments which have high unmet needs and higher acceptability for innovative therapies. Furthermore, across the biologics sub-segments, monoclonal antibodies (mAb) and bioengineered vaccines are amongst the highest contributing segments, with most companies having a strong focus on developing a mAb pipeline. On the other hand, cell and gene therapy are expected to show a strong potential, especially across the rare diseases market, with leading companies like Amgen, Sanofi, Pfizer, etc., investing in molecules in the early stages of clinical development. These molecules, if approved, have the potential of becoming key blockbuster products, propelling the market by more than 20% in the next few years. To achieve expertise across specific therapy areas and biologic sub-segments, bio-pharma companies collaborate with Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs), and digital and medical equipment companies that provide access to innovative proprietary technologies for research and development activities and to optimize the manufacturing process of complex biologics. Alongside industry and academic research collaborations, companies are also focusing on partnering with IT players such as IBM Watson, Intel etc., which provide technologically advanced solutions for conducting clinical trials to support complex drug manufacturing processes, thus creating integrated business models in addition to the above mentioned strategic analysis, a detailed biologic product pipeline, and a SWOT analysis of the key players has been undertaken.

    Click image to view it in full size

    • Fill form to receive complimentary access to the executive summary
    • * indicates mandatory fields
    • Firstname*
    • Lastname*
    • Company*
    • Job Title*
    • Business Phone*
    • Job Function*
    • Business Email*
    • Are you in the media?*
    • Looking to accelerate growth? We can help! Tell us which of the following services you would like to learn more about?
    • Growth Workshop and Customized Consulting Projects specific to your needs and Growth Objectives
      • Frost & Sullivan’s Growth Consulting Model provides specific tools and expertise to support clients through all five phases of the growth cycle: From developing a pipeline of growth opportunities to evaluating and prioritizing those opportunities to formulating and implementing go-to-market strategies to ongoing monitoring. The objective of the Growth Model is to identify your company’s Growth Zone and help you capture the most attractive opportunities.
    • Growth Partnership Services, comprehensive intelligence on market insights, mega trends, and emerging technologies
      • Growth Partnership Service identifies growth opportunities around your market, mitigates risk through in-depth research analysis, provides a global market perspective, and optimizes growth development strategies.
    • Scheduling a Growth Strategy Dialogue session, an interactive dialogue hosted by an industry expert
      • Talk to an analyst today to know more by signing up for a complimentary Growth Strategy Dialogue, an interactive conversation with an analyst regarding growth opportunities in your market.